Merck Collaborates with Yumanity to Accelerate the Development of Two Therapies Targeting Neurodegenerative Diseases

Shots:

• Yumanity will receive $500M upfront and milestones along with royalties on net sales of therapies, in exchange Merck to get an exclusive right to two novels Yumanity’s pipeline programs for the treatment of ALS and FTLD
• The collaboration integrates Yumanity’s drug discovery platform with Merck’s development and commercialization expertise in neuroscience  
•  Yumanity and Merck will collaborate to advance the two preclinical programs during the research term, after which Merck will lead the clinical development and commercialization  

Click here to read full press release/ article | Ref: Merck | Image: Daily Express